Prokidney Corp. (PROK)
NASDAQ:PROK
Want to see PROK full AI Analyst Report?
PROK Stock Chart & Stats
$1.66
-$0.14(-7.65%)
At close: 4:00 PM EST
$1.66
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$0.54 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)919.24K
Market Cap
$528.43M
Enterprise Value$465.79M
Total Cash (Recent Filing)$224.94M
Total Debt (Recent Filing)$3.78M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding141,987,950
10 Day Avg. Volume942,669
30 Day Avg. Volume919,237
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue523.95
Enterprise Value/Gross Profit-233.48
Enterprise Value/Ebitda-2.99
Forecast
1Y Price Target
$5.42Price Target Upside226.20% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$408.00K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPositive Phase 2 results showed statistically significant improvements in kidney function after bilateral injection, reinforcing the therapy's clinical rationale and supporting the registrational trial design.
Regulatory PathwayAnalyst notes pursuit of an FDA-aligned accelerated approval pathway for rilparencel could enable a faster regulatory review and support earlier market entry if surrogate endpoint results justify a filing.
Statistical RigorMaintaining statistical power for the pivotal trial preserves the ability to detect meaningful treatment effects and supports the credibility of data intended for regulatory decisions.
Bears Say
Approval Timing UncertaintyLower total patient enrollment to achieve the same event target increases uncertainty around the timing of full approval because event accrual may proceed more slowly.
Confirmatory Trial DurationReduction in confirmatory study enrollment while keeping the same event requirement implies the confirmatory analysis will take longer to complete, extending the time to reach final results.
Development And Commercial RiskSmaller confirmatory enrollment raises execution risk for the long-term approval strategy and could complicate commercial planning if confirmatory results are delayed.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $0.54 and its highest was $7.13 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $528.43M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Aug 06, 2026 which is in 71 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on May 15, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.002.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -0.14.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 141,987,950 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -2.924%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.42 (226.20% Upside)
$5.42 (226.20% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 54.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
137.77%
12-Months-Change
Fundamentals
Return on Equity
7.40%
Trailing 12-Months
Asset Growth
-27.90%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.42
▲(226.20% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
70.93% Insiders
2.74% Mutual Funds
12.58% Other Institutional Investors
12.42% Public Companies and
Individual Investors